

Trading Update

Advanced Health Intelligence Ltd (ASX/NASDAQ: AHI) (“AHI” or “the Company”) refers to the increase in the trading price, and an increase in the volume of trading, of the Company’s American Depositary Shares (ADSs) that trade on Nasdaq during the trading day on 21 June 2023 (New York time).

The Company believes that its announcement of the execution of the letter of intent with UAE-based e-script medicine management company Pharmak Direct on 21 June 2023 (Perth time) may have had an impact on the trading price and trading volumes of the Company’s ADSs on Nasdaq mentioned above.

AHI wishes to confirm that it remains in the compliance with the ASX Listing Rules, in particular ASX Listing Rule 3.1. AHI also confirms that there is not currently any “excluded information” with respect to AHI that has been withheld from the market in reliance on a carve out from ASX Listing Rule 3.1.

The Board of Advanced Health Intelligence Ltd has approved this announcement.

For more information, contact: .

Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech